Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q1 FY2026-27 Earnings Presentation
14 slides from Orchid Pharma's earnings presentation, Aug 20, 2026
Slide 1: Investors Presentation - Quarter I FY 2026-27 (cover letter to exchanges)
· - "". •• OrchidPharm~W - - A Dhanuka Group Company - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - August 20, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort,
Slide 2: Orchid Pharma - A Dhanuka Group Company
FROM OrchidPharma/ ‘A Dhanuka Group Company Nature Inspired Fermentation KSMs & API API Formulations Finished Dosage Origins & Biotransformation Process Manufacturing & Fill Finish For A Healthier World Development 2026
Slide 3: Safe Harbor
Safe Harbor 2026 OrchidPharma [A Dhanuka Group Company This presentation and the accompanying slides (the “Presentation” ) , which have been prepared by Orchid Pharma Limited (the “Company’ ), have been prepared solely for information purposes and do not constitute any offer, recommendation or invit
Slide 4: Orchid Pharma Limited
Orchid Pharma Limited One of the most integrated anti-infective platform globally > Built on 30 years of cephalosporin expertise. > Proven by EXBLIFEP - India's only novel antibiotic. > Anchored by India's only USFDA sterile cephalosporin approval. > Extending into AMR and regulated markets. OrchidP
Slide 5: Orchid is at an inflection point
OrchidPharma? [A Dhanuka Group Company Orchid is at an inflection point at The merger is complete and the platform is coming together as one An Integrated Cephalosporin Platform The core API business is ready to create long-term value Multiple growth engines are moving from concept to execution acro
Slide 6: Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. under the NCLT-sanctioned Scheme
Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. under the NCLT-sanctioned Scheme.
Slide 7: Bringing two entities together
Bringing two entities together Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. - Orchid Pharma Ltd. * India’ s USFDA-approved sterile cephalosporin leader Pharma business established in 1998 + DLL’s pharmaceutical capabilities absorbed under the sanctioned Leader in halosporin antibiot
Slide 8: Financial Performance Q1 FY27
OrchidPharma¥ Financial i, Performance —— Q1 FY27
Slide 9: : ( ) ( ) - - % % + % - % -
: ( ) ( ) - - % % + % - % - % + % + % - % % % % % % - % ( ) -
Slide 10: FY26 Financial Performance: Standalone (Revised)
FY26 Financial Performance: Standalone (Revised) OrchidPharmay [A Dhanuka Group Company 187 132 1,397 95 1,233, 35 FY25, FY26 FY25 FY26 FY25, FY26 Gross Margin EBITDA Margin 36% 13% 8% 32% 2026 LJ orchidpharma.com QQ FY25 FY26 FY25, FY26
Slide 11: Q1 FY27 Financial Performance: Standalone
Q1 FY27 Financial Performance : Standalone OrchidPharma? Total Revenue EBITDA PAT 304 25 R QIFY26 QIFY27 QIFY26 QUFY27 3 QIFY26, QUFY27 8% 33% 3% LJ QIFY26 QIFY27 QIFY26 QIFY27 2026 orchidpharma.com (10
Slide 12: Particulars Q1 FY27 Q1 FY26
& ( ) ( ) Particulars Q1 FY27 Q1 FY26 FY26 Jun 2026 Jun 2025 Year ended ( ) ( ) - - & /( ) & ( ) – – ( ) /( ) ( ) – – – /( ) & – – – /( ) ( ) ( ) ( ) ( ) — & (₹) ( )
Slide 13: Particulars Q1 FY27 Q1 FY26
& ( ) ( ) Particulars Q1 FY27 Q1 FY26 FY26 Jun 2026 Jun 2025 Year ended ( ) ( ) - - & /( ) & ( ) – – ( ) /( ) ( ) – ( ) /( ) & ( ) /( ) ( ) ( ) ( ) ( ) — & (₹) ( )
Slide 14: OrchidPharma?
OrchidPharma? A Dhanuka Group Company